NASDAQ:FENC Adherex Technologies Q3 2025 Earnings Report $12.55 +0.24 (+1.95%) As of 09/3/2026 04:00 PM Eastern ProfileEarnings HistoryForecast Adherex Technologies EPS ResultsActual EPS-$0.02Consensus EPS -$0.08Beat/MissBeat by +$0.06One Year Ago EPSN/AAdherex Technologies Revenue ResultsActual Revenue$12.46 millionExpected Revenue$13.43 millionBeat/MissMissed by -$971.00 thousandYoY Revenue GrowthN/AAdherex Technologies Announcement DetailsQuarterQ3 2025Date11/13/2025TimeBefore Market OpensConference Call DateThursday, November 13, 2025Conference Call Time4:00PM ETUpcoming EarningsAdherex Technologies' Q3 2026 earnings is estimated for Thursday, November 12, 2026, based on past reporting schedules, with a conference call scheduled at 12:30 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsEarnings Release(8-K)Quarterly Report(10-Q) Adherex Technologies Earnings HeadlinesFennec Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 11, 2026August 5, 2026 | globenewswire.comFennec Announces Results of Annual MeetingJune 10, 2026 | globenewswire.comRickards Predicts: Trump to buy tiny $2 stock?Jim Rickards believes the Trump administration is about to take a direct stake in a $2 stock sitting on the largest mineral reserve in the country - enough gold for a new Fort Knox, enough copper to rebuild the U.S. electric grid 25 times over. The Trump administration has previously staked positions in MP Materials, Lithium America, Trilogy Metals, and USA Rare Earth - each time shares moved higher. A landmark policy decision expected before November 3 could reprice this stock from $2 to $20 or more within a year. | Paradigm Press (Ad)Adherex Technologies' PEDMARK push targets larger AYA market after record quarterMay 23, 2026 | msn.comFennec Pharmaceuticals Announces New Research Supporting Integration and Use of PEDMARK® at the 2026 ASCO Annual MeetingMay 21, 2026 | globenewswire.comFennec Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 18, 2026 | globenewswire.comSee More Adherex Technologies Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Adherex Technologies? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Adherex Technologies and other key companies, straight to your email. Email Address About Adherex TechnologiesFennec Pharmaceuticals Inc., a biopharmaceutical company, develops product candidates for use in the treatment of cancer in the United States. Its lead product candidate is the Sodium Thiosulfate, which has completed the Phase III clinical trial for the prevention of cisplatin induced hearing loss or ototoxicity in children. The company was formerly known as Adherex Technologies (NASDAQ:FENC) and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was founded in 1996 and is based in Research Triangle Park, North Carolina.View Adherex Technologies ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles AeroVironment’s $465 Million Army Laser Win Expands Its Counter-Drone OpportunityThe Path to $230 Billion: Broadcom Outlines the Next Phase of Its AI Growth StoryPalo Alto Networks Is Expensive—But Its Growth Is AcceleratingMongoDB’s Spending Fears Collide With a Much Stronger Growth StoryGitLab’s Earnings Beat Just Gave Software Bulls a New SaaSpocalypse TestWith the RSI at a Record Low, Is It Time to Go Bargain Hunting on Burlington?Enova’s Earnings Surge Meets a Valuation Test Upcoming Earnings Oracle (9/8/2026)Adobe (9/10/2026)FedEx (9/17/2026)Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/8/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
